Microbiotix
Microbiotix, Inc.: A US-based biopharmaceutical firm developing drugs for serious infectious diseases.
Founded
1998Microbiotix, Inc.: A US-based biopharmaceutical firm developing drugs for serious infectious diseases.
Microbiotix, Inc., founded in Worcester, Massachusetts, is a clinical-stage biopharmaceutical company dedicated to discovering and developing proprietary small molecule drugs aimed at treating serious infectious diseases, including those caused by multi-drug resistant pathogens. The company's core mission is to address unmet medical needs in the field of infectious diseases through innovative therapeutic solutions. Microbiotix's lead product, MBX-400, is a novel nucleoside analog dual DNA polymerase/kinase inhibitor designed for the treatment of human cytomegalovirus (CMV), which has successfully completed Phase 1 clinical testing.
Notable figures affiliated with Microbiotix include its team of experienced scientists and industry experts who drive its research and development efforts. The company has garnered attention from key investors in the biopharmaceutical sector, supporting its mission to combat infectious diseases. Microbiotix's significant achievement with MBX-400 highlights its potential impact on public health by providing new treatments for challenging infections. Through its innovative approach, Microbiotix aims to make a substantial contribution to the global fight against infectious diseases.
Companies similar to Microbiotix include Microbion, X-Biotix Therapeutics, Taxis Pharmaceuticals and BioPlx.
Microbiotix was founded in 1998.
Microbiotix's headquarters is located in Worcester, MA, US.
Microbiotix's most recent funding round was for $2.1M (USD) in November 2022.
As of Nov 21, 2022, Microbiotix has raised a total of $6.5M (USD).
Microbiotix has 25 employees as of Feb 4, 2024.
Taxis Pharmaceuticals
taxispharma.com
